» Articles » PMID: 26209956

A Pharmacometric Case Study Regarding the Sensitivity of Structural Model Parameter Estimation to Error in Patient Reported Dosing Times

Overview
Publisher Springer
Specialty Pharmacology
Date 2015 Jul 27
PMID 26209956
Authors
Affiliations
Soon will be listed here.
Abstract

Although there is a body of literature focused on minimizing the effect of dosing inaccuracies on pharmacokinetic (PK) parameter estimation, most of the work centers on missing doses. No attempt has been made to specifically characterize the effect of error in reported dosing times. Additionally, existing work has largely dealt with cases in which the compound of interest is dosed at an interval no less than its terminal half-life. This work provides a case study investigating how error in patient reported dosing times might affect the accuracy of structural model parameter estimation under sparse sampling conditions when the dosing interval is less than the terminal half-life of the compound, and the underlying kinetics are monoexponential. Additional effects due to noncompliance with dosing events are not explored and it is assumed that the structural model and reasonable initial estimates of the model parameters are known. Under the conditions of our simulations, with structural model CV % ranging from ~20 to 60 %, parameter estimation inaccuracy derived from error in reported dosing times was largely controlled around 10 % on average. Given that no observed dosing was included in the design and sparse sampling was utilized, we believe these error results represent a practical ceiling given the variability and parameter estimates for the one-compartment model. The findings suggest additional investigations may be of interest and are noteworthy given the inability of current PK software platforms to accommodate error in dosing times.

References
1.
Lu J, Gries J, Verotta D, Sheiner L . Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn. 2001; 28(4):343-62. DOI: 10.1023/a:1011582713692. View

2.
Soy D, Beal S, Sheiner L . Population one-compartment pharmacokinetic analysis with missing dosage data. Clin Pharmacol Ther. 2004; 76(5):441-51. DOI: 10.1016/j.clpt.2004.07.010. View

3.
Diaz E, LEVINE H, Sullivan M, Sernyak M, Hawkins K, Cramer J . Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci. 2001; 26(4):325-9. PMC: 167186. View

4.
Gibiansky L, Gibiansky E, Cosson V, Frey N, Schaedeli Stark F . Methods to detect non-compliance and reduce its impact on population PK parameter estimates. J Pharmacokinet Pharmacodyn. 2014; 41(3):279-89. DOI: 10.1007/s10928-014-9364-2. View

5.
Parker C, Chen Z, Price M, Gross R, Metlay J, Christie J . Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007; 22(9):1254-9. PMC: 2219760. DOI: 10.1007/s11606-007-0233-1. View